Jared Davis Huling

Jared Davis Huling

Auto-generated profile, based on publicly available information

Jared Davis Huling

Division of Biostatistics and Health Data Science University of Minnesota

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Causal Inference
Verified
Journal Article
Open access
PDF file
JHJared D. Huling
Jared D. Huling
SMSimon Mak
Simon Mak
Bias in causal comparisons has a correspondence with distributional imbalance of covariates between treatment groups. Weighting strategies such as inverse propensity score weighting attempt to mitigate bias by either modeling the treatment assignment mechanism or balancing specified covariate moments. This article introduces a new weighting method, called energy balancing, which instead aims to balance weighted covariate distributions. By directly targeting distributional imbalance, the proposed weighting strategy can be flexibly utilized in a wide variety of causal analyses without the need for careful model or moment specification. Our energy balancing weights (EBW) approach has several advantages over existing weighting techniques. First, it offers a model-free and robust approach for obtaining covariate balance that does not require tuning parameters, obviating the need for modeling decisions of secondary nature to the scientific question at hand. Second, since this approach is based on a genuine measure of distributional balance, it provides a means for assessing the balance induced by a given set of weights for a given dataset. We demonstrate the effectiveness of this EBW approach in a suite of simulation experiments, and in studies on the safety of right heart catheterization and on three additional studies using electronic health record data.

10 July 2023 in Journal of the American Statistical Association
Verified
Journal Article
Closed access
JHJared D. Huling
Jared D. Huling
NGNoah Greifer
Noah Greifer
GCGuanhua Chen
Guanhua Chen

24 December 2022 in medRxiv
Verified
Preprint
Open access
PDF file
CBCarolyn T. Bramante
Carolyn T. Bramante
JBJohn B. Buse
John B. Buse
DLDavid Liebovitz
David Liebovitz
JNJacinda Nicklas
Jacinda Nicklas
MPMichael Puskarich
Michael Puskarich
DBDavid Boulware
David Boulware
Background: Long Covid is an emerging chronic illness potentially affecting millions, sometimes preventing the ability to work or participate in normal daily activities. COVID-OUT was an investigator-initiated, multi-site, phase 3, randomized, quadruple-blinded placebo-controlled clinical trial ( NCT04510194 ). The design simultaneously assessed three oral medications (metformin, ivermectin, fluvoxamine) using two by three parallel treatment factorial assignment to efficiently share placebo controls and assessed Long Covid outcomes for 10 months to understand whether early outpatient treatment of SARS-CoV-2 with metformin, ivermectin, or fluvoxamine prevents Long Covid. Methods: This was a decentralized, remotely delivered trial in the US of 1,125 adults age 30 to 85 with overweight or obesity, fewer than 7 days of symptoms, and enrolled within three days of a documented SARS-CoV-2 infection. Immediate release metformin titrated over 6 days to 1,500mg per day 14 days total; ivermectin 430mcg/kg/day for 3 days; fluvoxamine, 50mg on day one then 50mg twice daily through 14 days. Medical-provider diagnosis of Long Covid, reported by participant by day 300 after randomization was a pre-specified secondary outcome; the primary outcome of the trial was severe Covid by day 14. Result: The median age was 45 years (IQR 37 to 54), 56% female of whom 7% were pregnant. Two percent identified as Native American; 3.7% as Asian; 7.4% as Black/African American; 82.8% as white; and 12.7% as Hispanic/Latino. The median BMI was 29.8 kg/m 2 (IQR 27 to 34); 51% had a BMI >30kg/m 2 . Overall, 8.4% reported having received a diagnosis of Long Covid from a medical provider: 6.3% in the metformin group and 10.6% in the metformin control; 8.0% in the ivermectin group and 8.1% in the ivermectin control; and 10.1% in the fluvoxamine group and 7.5% in the fluvoxamine control. The Hazard Ratio (HR) for Long Covid in the metformin group versus control was 0.58 (95% CI 0.38 to 0.88); 0.99 (95% CI 0.592 to 1.643) in the ivermectin group; and 1.36 in the fluvoxamine group (95% CI 0.785 to 2.385). Conclusions: There was a 42% relative decrease in the incidence of Long Covid in the metformin group compared to its blinded control in a secondary outcome of this randomized phase 3 trial. Trial registration: NCT04510194. IND: 152439

20 February 2022 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
CBCarolyn T Bramante
Carolyn T Bramante
JPJennifer L Proper
Jennifer L Proper
DBDavid Boulware
David Boulware
AKAmy B Karger
Amy B Karger
TMThomas Murray
Thomas Murray
JHJared D Huling
Jared D Huling
Data conflict on whether vaccination decreases severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load. The objective of this analysis was to compare baseline viral load and symptoms between vaccinated and unvaccinated adults enrolled in a randomized trial of outpatient coronavirus disease 2019 (COVID-19) treatment. Baseline data from the first 433 sequential participants enrolling into the COVID-OUT trial were analyzed. Adults aged 30–85 with a body mass index (BMI) ≥25 kg/m2 were eligible within 3 days of a positive SARS-CoV-2 test and <7 days of symptoms. Log10 polymerase chain reaction viral loads were normalized to human RNase P by vaccination status, by time from vaccination, and by symptoms. Two hundred seventy-four participants with known vaccination status contributed optional nasal swabs for viral load measurement: median age, 46 years; median (interquartile range) BMI 31.2 (27.4–36.4) kg/m2. Overall, 159 (58%) were women, and 217 (80%) were White. The mean relative log10 viral load for those vaccinated <6 months from the date of enrollment was 0.11 (95% CI, –0.48 to 0.71), which was significantly lower than the unvaccinated group (P = .01). Those vaccinated ≥6 months before enrollment did not differ from the unvaccinated with respect to viral load (mean, 0.99; 95% CI, –0.41 to 2.40; P = .85). The vaccinated group had fewer moderate/severe symptoms of subjective fever, chills, myalgias, nausea, and diarrhea (all P < .05). These data suggest that vaccination within 6 months of infection is associated with a lower viral load, and vaccination was associated with a lower likelihood of having systemic symptoms.

1 June 2022 in American Journal of Public Health
Verified
Journal Article
Closed access
JHJared D. Huling
Jared D. Huling
RARobin R. Austin
Robin R. Austin
SLSheng-Chieh Lu
Sheng-Chieh Lu
MDMary M. Doran
Mary M. Doran
VSVicki J. Swarr
Vicki J. Swarr
KMKaren A. Monsen
Karen A. Monsen
Objectives. To examine public health nurse (PHN) intervention tailoring through the Colorado Nurse Support Program (NSP). Our 2 specific aims were to describe the NSP program and its outcomes and to determine the effects of modifying interventions on short- and long-term outcomes among NSP clients.Methods. In our retrospective causal investigation of 150 families in Colorado in 2018–2019, intervention effects were modeled via longitudinal modified treatment policy analyses.Results. Families served by PHNs improved in terms of knowledge, behavior, and status outcomes after receiving multidimensional, tailored home visiting interventions. Case management interventions provided in the first month of PHN home visits had lasting effects on behavior outcomes, and 2 additional case management interventions in the first month were estimated to have even more of an impact.Conclusions. Modern causal inference methods and real-world PHN data revealed a nuanced, fine-grained understanding of the real impact of tailored PHN interventions.Public Health Implications PHN programs such as the NSP and use of the Omaha System should be supported and extended to advance evaluations of intervention effectiveness and knowledge discovery and improve population health. (Am J Public Health. 2022;112(S3):S306–S313. https://doi.org/10.2105/AJPH.2022.306792 )

19 June 2023 in Biometrika
Verified
Journal Article
Closed access
PDF file
RCRui Chen
Rui Chen
JHJared D Huling
Jared D Huling
GCGuanhua Chen
Guanhua Chen
MYMenggang Yu
Menggang Yu
Summary: Learning individualized treatment rules is an important topic in precision medicine. Current literature mainly focuses on deriving individualized treatment rules from a single source population. We consider the observational data setting when the source population differs from a target population of interest. Compared with causal generalization for the average treatment effect that is a scalar quantity, individualized treatment rule generalization poses new challenges due to the need to model and generalize the rules based on a prespecified class of functions that may not contain the unrestricted true optimal individualized treatment rule. The aim of this paper is to develop a weighting framework to mitigate the impact of such misspecification, and thus facilitate the generalizability of optimal individualized treatment rules from a source population to a target population. Our method seeks covariate balance over a nonparametric function class characterized by a reproducing kernel Hilbert space and can improve many individualized treatment rule learning methods that rely on weights. We show that the proposed method encompasses importance weights and overlap weights as two extreme cases, allowing for a better bias-variance trade-off in between. Numerical examples demonstrate that the use of our weighting method can greatly improve individualized treatment rule estimation for the target population compared with other weighting methods.